Maxim Group Maintains Buy on Compass Pathways, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 75.8%

Neg 0% Neu 0% Pos 75.8%

Maxim Group analyst Jason McCarthy maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $12 to $20.